{"schema_version":"secwatch.filing_event.v1","accession":"0001274737-22-000067","form_type":"8-K","ticker":"XGN","cik":"0001274737","company_name":"EXAGEN INC.","filed_at":"2022-10-20T23:59:59+00:00","discovered_at":"2026-05-14T18:03:49.965263+00:00","generated_at":"2026-06-23T02:12:00.928103+00:00","sec_items":["5.02","7.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Exagen names John Aballi CEO, succeeding Ron Rocca who resigned","bullets":["John Aballi appointed CEO/President and board member effective Oct 16, 2022, replacing Ron Rocca after 11 years.","Aballi previously SVP/GM Urology and CLIA COO at Veracyte; grew urology unit to $120M+ revenue annually.","Aballi receives base salary $525,000, target bonus 50% of base, equity award of 350,000 shares/units vesting 4 years.","Ron Rocca severance: lump sum $424,875, pro-rated incentive compensation, and 9 months COBRA reimbursement.","Rocca's resignation not due to any disagreement with company's operations, policies, or practices."],"urls":{"canonical":"https://secwatch.observer/filing/0001274737-22-000067","json":"https://secwatch.observer/filing/0001274737-22-000067.json","markdown":"https://secwatch.observer/filing/0001274737-22-000067.md","text":"https://secwatch.observer/filing/0001274737-22-000067.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1274737/000127473722000067/0001274737-22-000067-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1274737/000127473722000067/exdx-20221016.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-23T02:12:00.928103+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"2b5f60c624","claim":"Fortunato Ron Rocca resigned as President and Chief Executive Officer at EXAGEN INC..","evidence_excerpt":"Fortunato Ron Rocca who resigned as President and Chief Executive Officer of the Company and as a member of the Board of Directors, effective as of October 16, 2022.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1274737/000127473722000067/0001274737-22-000067-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"President and Chief Executive Officer"}],"fact_type":"executive_change"},{"claim_id":"dec7ebfa50","claim":"John Aballi was appointed as President and Chief Executive Officer at EXAGEN INC..","evidence_excerpt":"John Aballi has been appointed as President and Chief Executive Officer of the Company and as a member of the board of directors of the Company","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1274737/000127473722000067/0001274737-22-000067-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"President and Chief Executive Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}